Omacetaxine mepesuccinate

The study evaluates decitabine combined with CHAG regimen for R/R AML, achieving CR in 74.2% and ORR of 82.2% with fewer side effects. Median RFS was 4.3 months and median OS was 7.75 months. The regimen showed deeper remissions, especially in patients with WT1 gene positivity, AML1-ETO fusion gene positivity, and NPM1 mutation. The study suggests a new treatment option for R/R AML but acknowledges limitations due to its single-center, retrospective nature and short observation time.

Prostate cancer adapts to hormonal therapies by rewiring molecular pathways, necessitating new drug targets. Research focuses on mRNA translation as a weak link in tumor growth, potentially leading to new therapeutic strategies for advanced prostate cancer.

Pomalidomide significantly lowered Epistaxis Severity Score and improved health-related quality of life in HHT patients, according to the Phase II PATH-HHT trial. The study, published in The New England Journal of Medicine, showed a mean reduction of −0.94 points in Epistaxis Severity Score and a −1.4 point improvement in HHT-specific quality-of-life score. Adverse events were more common with pomalidomide, but the trial demonstrated its efficacy for HHT-related epistaxis, potentially offering a new treatment option for this population.

Cleveland Clinic researchers found pomalidomide, a cancer drug, effectively treats hereditary hemorrhagic telangiectasia (HHT), reducing nosebleed severity and improving quality of life in a clinical trial. The trial, halted early due to promising results, involved 144 adults across 11 centers, showing fewer blood transfusions needed. Pomalidomide, FDA-approved for bone marrow cancer, offers hope for HHT management, with further research planned.

A bone marrow cancer drug, pomalidomide, was found safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder, according to a clinical trial supported by the NIH. Patients experienced reduced nosebleeds, fewer transfusions, and improved quality of life. The trial was stopped early due to significant positive results, published in the New England Journal of Medicine.